Nephrogenic systemic fibrosis

American Journal of Roentgenology

Volumn 199, Issue 1, 2012, Pages

  Kaewlai, Rathachai ^a   Abujudeh, Hani ^b  

^a MAHIDOL UNIVERSITY   (Thailand)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Gadolinium based contrast agents; Kidney function; MRI; Nephrogenic systemic fibrosis (NSF)

Indexed keywords

ECHOVIST; GADOBENATE DIMEGLUMINE; GADOBUTROL; GADODIAMIDE; GADOFOSVESET; GADOLINIUM; GADOLINIUM PENTETATE; GADOTERATE MEGLUMINE; GADOTERIDOL; GADOVERSETAMIDE; GADOXETIC ACID; IMATINIB; IMMUNOSUPPRESSIVE AGENT; STEROID;

ACUTE KIDNEY FAILURE; CHRONIC KIDNEY DISEASE; CLINICAL FEATURE; CONTRAST ENHANCEMENT; DISEASE ASSOCIATION; FOOD AND DRUG ADMINISTRATION; GLOMERULUS FILTRATION RATE; HIGH RISK POPULATION; HISTOPATHOLOGY; HUMAN; IMAGE QUALITY; INFORMED CONSENT; KIDNEY DYSFUNCTION; KIDNEY TRANSPLANTATION; LABORATORY TEST; NEPHROGENIC SYSTEMIC FIBROSIS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; PATIENT EDUCATION; PATIENT SAFETY; PHYSIOTHERAPY; PREVALENCE; PRIORITY JOURNAL; RENAL REPLACEMENT THERAPY; REVIEW;

CONTRAST MEDIA; GADOLINIUM; HUMANS; IMAGE ENHANCEMENT; KIDNEY FUNCTION TESTS; MAGNETIC RESONANCE IMAGING; NEPHROGENIC FIBROSING DERMOPATHY;

EID: 84863638733     PISSN: 0361803X     EISSN: 15463141     Source Type: Journal    
DOI: 10.2214/AJR.11.8144     Document Type: Review

References (58)

1. Cowper SE, Robin HS, Steinberg SM, Su LD, Gupta S, LeBoit PE. Scleromyxedema-like cutaneous diseases in renal-dialysis patients. Lancet 2000; 356:1000-1001
2. Braverman IM, Cowper S. Nephrogenic systemic fibrosis. F1000 Med-Rep 2010; 2:84
3. Perez-Rodriguez J, Lai S, Ehst BD, Fine DM, Bluemke DA. Nephrogenic systemic fibrosis: incidence, associations, and effect of risk factor assessment - report of 33 cases. Radiology 2009; 250:371-377
4. Pietsch H, Raschke M, Ellinger-Ziegelbauer H, et al. The role of residual gadolinium in the induction of nephrogenic systemic fibrosis - like skin lesions in rats. Invest Radiol 2011; 46:48-56
5. Haemel AK, Sadowski EA, Shafer MM, Djamali A. Update on nephrogenic systemic fibrosis: are we making progress? Int J Dermatol 2011; 50:659-666
6. Girardi M, Kay J, Elston DM, Leboit PE, Abu-Alfa A, Cowper SE. Nephrogenic systemic fibrosis: clinicopathological definition and workup recommendations. J Am Acad Dermatol 2011; 65:1095-1106
7. Marckmann P, Skov L, Rossen K, et al. Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol 2006; 17:2359-2362 (Pubitemid 44300951)
8. Grobner T. Gadolinium: a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant 2006; 21:1104-1108
9. High WA, Ayers RA, Chandler J, Zito G, Cowper SE. Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis. J Am Acad Dermatol 2007; 56:21-26 (Pubitemid 46017000)
10. Boyd AS, Zic JA, Abraham JL. Gadolinium deposition in nephrogenic fibrosing dermopathy. J Am Acad Dermatol 2007; 56:27-30 (Pubitemid 44969309)
11. Abujudeh HH, Kaewlai R, Kagan A, et al. Nephrogenic systemic fibrosis after gadopentetate dimeglumine exposure: case series of 36 patients. Radiology 2009; 253:81-89
12. Collidge TA, Thomson PC, Mark PB, et al. Gadolinium-enhanced MR imaging and nephrogenic systemic fibrosis: retrospective study of a renal replacement therapy cohort. Radiology 2007; 245:168-175 (Pubitemid 47417800)
13. Sadowski EA, Bennett LK, Chan MR, et al. Nephrogenic systemic fibrosis: risk factors and incidence estimation. Radiology 2007; 243:148-157 (Pubitemid 46579705)
14. Kuo PH, Kanal E, Abu-Alfa AK, Cowper SE. Gadolinium-based MR contrast agents and nephrogenic systemic fibrosis. Radiology 2007; 242:647-649
15. Rydahl C, Thomsen HS, Marckmann P. High prevalence of nephrogenic systemic fibrosis in chronic renal failure patients exposed to gadodiamide, a gadolinium-containing magnetic resonance contrast agent. Invest Radiol 2008; 43:141-144
16. Christensen KN, Lee CU, Hanley MM, Leung N, Moyer TP, Pittelkow MR. Quantification of gadolinium in fresh skin and serum samples from patients with nephrogenic systemic fibrosis. J Am Acad Dermatol 2011; 64:91-96
17. Pietsch H, Pering C, Lengsfeld P, et al. Evaluating the role of zinc in the occurrence of fibrosis of the skin: a preclinical study. J Magn Reson Imaging 2009; 30:374-383
18. Sieber MA, Pietsch H, Walter J, Haider W, Frenzel T, Weinmann HJ. A preclinical study to investigate the development of nephrogenic systemic fibrosis: a possible role for gadolinium-based contrast media. Invest Radiol 2008; 43:65-75
19. Fretellier N, Idee JM, Guerret S, et al. Clinical, biological, and skin histopathologic effects of ionic macrocyclic and nonionic linear gadolinium chelates in a rat model of nephrogenic systemic fibrosis. Invest Radiol 2011; 46:85-93
20. Wiesinger B, Kehlbach R, Hemsen J, et al. Effects of magnetic resonance imaging contrast agents on human umbilical vein endothelial cells and evaluation of magnetic resonance imaging contrast media-triggered transforming growth factor-beta induction in dermal fibroblasts (HSF) as a model for nephrogenic systemic fibrosis. Invest Radiol 2011; 46:71-76
21. Abu-Alfa A. The impact of NSF on the care of patients with kidney disease. J Am Coll Radiol 2008; 5:45-52
22. American College of Radiology (ACR) Website. ACR manual on contrast media, version 7. www.acr.org/SecondaryMainMenuCategories/quality-safety/ contrast-manual/FullManual.aspx. Updated 2010. Accessed December 25, 2011
23. DeHoratius DM, Cowper SE. Nephrogenic systemic fibrosis: an emerging threat among renal patients. Semin Dial 2006; 19:191-194 (Pubitemid 43742654)
24. Bardin T, Richette P. Nephrogenic systemic fibrosis. Curr Opin Rheumatol 2010; 22:54-58
25. Evenepoel P, Zeegers M, Segaert S, et al. Nephrogenic fibrosing dermopathy: a novel, disabling disorder in patients with renal failure. Nephrol Dial Transplant 2004; 19:469-473 (Pubitemid 38196001)
26. Cowper SE, Su LD, Bhawan J, Robin HS, LeBoit PE. Nephrogenic fibrosing dermopathy. Am J Dermatopathol 2001; 23:383-393 (Pubitemid 32938907)
27. Cowper SE. Nephrogenic fibrosing dermopathy: the first 6 years. Curr Opin Rheumatol 2003; 15:785-790 (Pubitemid 38156308)
28. Sanyal S, Marckmann P, Scherer S, Abraham JL. Multiorgan gadolinium (Gd) deposition and fibrosis in a patient with nephrogenic systemic fibrosis: an autopsy-based review. Nephrol Dial Transplant 2011; 26:3616-3626
29. Thomsen HS. Nephrogenic systemic fibrosis: a serious late adverse reaction to gadodiamide. Eur Radiol 2006; 16:2619-2621 (Pubitemid 44823915)
30. Tweedle MF, Wedeking P, Kumar K. Biodistribution of radiolabeled, formulated gadopentetate, gadoteridol, gadoterate, and gadodiamide in mice and rats. Invest Radiol 1995; 30:372-380
31. Tweedle MF. "Stability" of gadolinium chelates. (letter) Br J Radiol 2007; 80:583-584; author reply, 584-585
32. Frenzel T, Lengsfeld P, Schirmer H, Hutter J, Weinmann HJ. Stability of gadolinium-based magnetic resonance imaging contrast agents in human serum at 37 degrees C. Invest Radiol 2008; 43:817-828
33. Hope TA, Herfkens RJ, Denianke KS, LeBoit PE, Hung YY, Weil E. Nephrogenic systemic fibrosis in patients with chronic kidney disease who received gadopentetate dimeglumine. Invest Radiol 2009; 44:135-139
34. Wertman R, Altun E, Martin DR, et al. Risk of nephrogenic systemic fibrosis: evaluation of gadolinium chelate contrast agents at four American universities. Radiology 2008; 248:799-806
35. Morcos SK, Thomsen HS. Nephrogenic systemic fibrosis: more questions and some answers. Nephron Clin Pract 2008; 110:c24-c31; discussion, c32
36. Broome DR. Nephrogenic systemic fibrosis associated with gadolinium based contrast agents: a summary of the medical literature reporting. Eur J Radiol 2008; 66:230-234
37. Kribben A, Witzke O, Hillen U, Barkhausen J, Daul AE, Erbel R. Nephrogenic systemic fibrosis: pathogenesis, diagnosis, and therapy. J Am Coll Cardiol 2009; 53:1621-1628
38. National Kidney Disease Education Program. GFR MDRD calculator for adults (conventional units). nkdep.nih.gov/professionals/gfr-calculators/idms-con.htm. Updated January 27, 2011. Accessed December 25, 2011
39. Weigle JP, Broome DR. Nephrogenic systemic fibrosis: chronic imaging findings and review of the medical literature. Skeletal Radiol 2008; 37:457-464
40. Su HS, Nazarian RM, Scott JA. Case report: appearance of nephrogenic fibrosing dermopathy on a bone scan. Br J Radiol 2009; 82:e35-e36
41. Galan A, Cowper SE, Bucala R. Nephrogenic systemic fibrosis (nephrogenic fibrosing dermopathy). Curr Opin Rheumatol 2006; 18:614-617 (Pubitemid 44607415)
42. Kay J, High WA. Imatinib mesylate treatment of nephrogenic systemic fibrosis. Arthritis Rheum 2008; 58:2543-2548
43. Kay J. Treatment of nephrogenic systemic fibrosis: update on imatinib mesylate. In: Fourth Annual Symposium on Nephrogenic Systemic Fibrosis and Gadolinium-Based Contrast Agents. New York, NY: NY Academy of Sciences, 2010
44. Cuffy MC, Singh M, Formica R, et al. Renal transplantation for nephrogenic systemic fibrosis: a case report and review of the literature. Nephrol Dial Transplant 2011; 26:1099-1101
45. Cowper SE. Nephrogenic systemic fibrosis: the nosological and conceptual evolution of nephrogenic fibrosing dermopathy. Am J Kidney Dis 2005; 46:763-765 (Pubitemid 41383957)
46. Auron A, Shao L, Warady BA. Nephrogenic fibrosing dermopathy in children. Pediatr Nephrol 2006; 21:1307-1311 (Pubitemid 44203458)
47. Jan F, Segal JM, Dyer J, LeBoit P, Siegfried E, Frieden IJ. Nephrogenic fibrosing dermopathy: two pediatric cases. J Pediatr 2003; 143:678-681 (Pubitemid 37452802)
48. Wang Y, Alkasab TK, Narin O, et al. Incidence of nephrogenic systemic fibrosis after adoption of restrictive gadolinium-based contrast agent guidelines. Radiology 2011; 260:105-111
49. Abujudeh HH, Rolls H, Kaewlai R, et al. Retrospective assessment of prevalence of nephrogenic systemic fibrosis (NSF) after implementation of a new guideline for the use of gadobenate dimeglumine as a sole contrast agent for magnetic resonance examination in renally impaired patients. J Magn Reson Imaging 2009; 30:1335-1340
50. Martin DR, Krishnamoorthy SK, Kalb B, et al. Decreased incidence of NSF in patients on dialysis after changing gadolinium contrast-enhanced MRI protocols. J Magn Reson Imaging 2010; 31:440-446
51. Kay J, Bazari H, Avery LL, Koreishi AF. Case records of the Massachusetts General Hospital: case 6-2008 - a 46-year-old woman with renal failure and stiffness of the joints and skin. N Engl J Med 2008; 358:827-838
52. Ting WW, Stone MS, Madison KC, Kurtz K. Nephrogenic fibrosing dermopathy with systemic involvement. Arch Dermatol 2003; 139:903-906 (Pubitemid 36898926)
53. United States Food and Drug Administration Website. Gadolinium-containing contrast agents for magnetic resonance imaging (MRI): Omniscan, OptiMARK, Magnevist, ProHance, and MultiHance. www.fda.gov/Safety/MedWatch/ SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm150564.htm. Updated December 22, 2006. Accessed September 30, 2011
54. United States Food and Drug Administration Website. FDA requests boxed warning for contrast agents used to improve MRI images. www.fda.gov/NewsEvents/ Newsroom/PressAnnouncements/2007/ucm108919.htm. Updated June 18, 2009. Accessed September 30, 2011
55. European Medicines Agency Website. Vasovist and nephrogenic systemic fibrosis (NSF). www.ema.europa.eu/docs/en-GB/document-library/Public-statement/ 2009/11/WC500015607.pdf. Accessed September 30, 2011
56. Kanal E, Barkovich AJ, Bell C, et al. ACR guidance document for safe MR practices: 2007. AJR 2007; 188:1447-1474 (Pubitemid 46866845)
57. United States Food and Drug Administration Website. Joint meeting of the Cardiovascular and Renal Drugs, and Drug Safety and Risk Management Advisory Committees. NDA# 21-711 Ablavar injection (gadofosveset trisodium) briefing document. www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/ Drugs/DrugSafetyandRisk-ManagementAdvisoryCommittee/UCM192010.pdf. Updated December 8, 2009. Accessed December 25, 2011
58. Juluru K, Vogel-Claussen J, Macura KJ, Kamel IR, Steever A, Bluemke DA. MR imaging in patients at risk for developing nephrogenic systemic fibrosis: protocols, practices, and imaging techniques to maximize patient safety. RadioGraphics 2009; 29:9-22